C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities with US$800 million of Assets Under Management. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics and healthcare services.
C-Bridge Capital is committed to support commercialization of cutting edge technologies and companies that fulfil unmet medical needs, thus continuously improving the standard and quality of care for patients.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.